Tandem Diabetes Care wins CE mark for Control-IQ+ use in adults with type 2 diabetes

Tandem Diabetes Care, Inc.

Tandem Diabetes Care, Inc.

TNDM

0.00
  • Tandem Diabetes Care secured CE mark in Europe for expanded use of its Control-IQ+ automated insulin delivery systems.
  • Clearance covers type 1 diabetes during pregnancy, supported by the CIRCUIT trial showing 12.6% more time in target glucose range.
  • Approval also extends to adults with type 2 diabetes, backed by the 2IQP trial showing a 0.9% A1C reduction.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tandem Diabetes Care Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260605572579) on June 05, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.